24/7 Market News Snapshot 10 September, 2025 – Amylyx Pharmaceuticals, Inc. Common Stock (NASDAQ:AMLX)

September 10, 2025

DENVER, Colo., 10 September, 2025 (www.247marketnews.com) – (NASDAQ:AMLX) are discussed in this article.
Amylyx Pharmaceuticals, Inc. has recently experienced notable growth, beginning the trading day at $11.50 and currently reaching $12.116, reflecting an impressive increase of around 15.28% from the previous closing of $10.510. The strong trading volume of 3.33 million shares indicates heightened investor interest and solid market liquidity. The stock appears to be breaking through resistance levels, suggesting potential for further gains. However, market observers remain attentive to the possibility of short-term corrections or consolidations as momentum builds, maintaining a bullish outlook based on this substantial performance.

In tandem with this market activity, Amylyx has announced the pricing of an underwritten public offering of 17,500,000 shares of common stock at a public offering price of $10.00 per share, aiming to generate gross proceeds of approximately $175 million. This offering consists solely of shares sold by the company, and underwriters have been granted a 30-day option to purchase an additional 2,625,000 shares. The transaction is expected to close around September 11, 2025, pending customary closing conditions.

The proceeds from the offering are earmarked for bolstering Amylyx’s operational capacity, including the commercial readiness of Avexitide, furthering research and development initiatives, and supporting general corporate purposes. Leerink Partners and Guggenheim Securities are leading the offering as book-running managers, with H.C. Wainwright & Co. serving as a lead manager. The offering falls under a previously filed shelf registration statement with the Securities and Exchange Commission.

Amylyx continues to demonstrate its commitment to addressing significant unmet medical needs by developing innovative therapies targeted at neurodegenerative and endocrine diseases, striving to enhance patient care while managing inherent risks associated with forward-looking statements.

Related news for (AMLX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.